<code id='7F48892DA2'></code><style id='7F48892DA2'></style>
    • <acronym id='7F48892DA2'></acronym>
      <center id='7F48892DA2'><center id='7F48892DA2'><tfoot id='7F48892DA2'></tfoot></center><abbr id='7F48892DA2'><dir id='7F48892DA2'><tfoot id='7F48892DA2'></tfoot><noframes id='7F48892DA2'>

    • <optgroup id='7F48892DA2'><strike id='7F48892DA2'><sup id='7F48892DA2'></sup></strike><code id='7F48892DA2'></code></optgroup>
        1. <b id='7F48892DA2'><label id='7F48892DA2'><select id='7F48892DA2'><dt id='7F48892DA2'><span id='7F48892DA2'></span></dt></select></label></b><u id='7F48892DA2'></u>
          <i id='7F48892DA2'><strike id='7F48892DA2'><tt id='7F48892DA2'><pre id='7F48892DA2'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:6279
          Sammy Kimball for STAT

          Who’s watching the drug price watchmen? Are RSV vaccines too expensive? And is it finally time for Novavax to shine?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Bob Herman joins us to explain his year-long investigation into some brazen conflicts of interest in the world of prescription drug pricing. Then, STAT’s Helen Branswell calls in to walk us through a news-packed week for vaccines, including weighty decisions for Covid-19 and RSV.

          advertisement

          For more on what we cover, here’s the story on conflicts of interest; here’s the latest on RSV vaccines; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          explore

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          BioAge raises $170M for combination therapy with Zepbound
          BioAge raises $170M for combination therapy with Zepbound

          Illustration:STAT;Source:EliLilly/APACaliforniabiotechdevelopingacombinationtherapywiththeobesitydru

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Steward Health Care expansion into Malta flopped

          TheformerStLuke'sHospitalinPieta,MaltawhichwassignedovertoVitalsandlaterStewardHealthCareoncondition